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Background: Information on the metabolic content in tissue has diagnostic and prognostic 
value when examining for example cancer and diseases of the brain. MR 
spectroscopy is a non-invasive method that allows quantification of 
metabolite concentrations in vivo, without the use of ionizing radiation, which 
makes the method highly attractive for both research and clinical applications.  
 
However, specialized software is required for generation of so called basis 
sets, which consist of information on the individual metabolites that are under 
investigation, and which are required for quantification. Furthermore, 
method- and MR vendor-specific information must be provided as the basis 
sets are being generated in order to yield reliable quantification results.  
 
A software for generation of basis sets was recently developed at the 
University of Gothenburg and validated for a preclinical MR system in a 
previous master thesis project. However, a standardized method for 
calculation of metabolite concentrations in vivo in the preclinical setting has 
not yet been developed. 
 
Therefore, the purpose of this work was to adapt, validate and apply a method 
for non-invasive quantification of metabolites from in vivo MR spectroscopy 




Method: The software, implemented in MATLAB and previously developed to 
simulate basis sets for the clinical MR system, was programmatically adapted 
to import pulse sequence parameters from the preclinical MR system. 
Validation of the adapted MATLAB software was done by MR spectroscopy 
measurements on a phantom solution with known concentrations of certain 
metabolites, followed by metabolite quantification using the LCModel 
software. Two in vivo experiments were performed to assess the applicability 
of the method in the preclinical setting: one on the healthy mouse brain and 
one on a mouse model of human cancer. The point resolved spectroscopy 




Results: The adaption of the software to the preclinical MR system was successful, 
resulting in simulated basis sets that could be well fitted to the spectra 
measured in the validation which, in turn, resulted in accurate determination 
of metabolite concentrations in the phantom. The in vivo experiments resulted 
in metabolic profiles of the cancer model and the healthy mouse brain that 
were in agreement with what has been found in previous studies. The method 
developed in this work will thus enable metabolite quantification of existing 
and future MR spectroscopy studies at the preclinical MR facility at the 
University of Gothenburg. 
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For a cell to grow, divide and perform its functions it requires energy. The process of converting 
nutrients to energy and biomass is called metabolism and, involved in this process, are 
intermediates and products of the metabolism called metabolites (Sand & Toverud, 2007). 
In cancer tissue, altered metabolism is required to provide for the rapid cell proliferation and 
adaption to the hostile microenvironment including, e.g., hypoxia. Thus, the metabolic content 
inside a tumour differs from that of healthy tissue, and knowledge of the tumour metabolic 
profile may provide important information on tumour aggressiveness, facilitate diagnosis and 
enable personalized treatment (Bokacheva et al., 2014).  
Magnetic resonance spectroscopy (MRS) is the only non-invasive method with the potential to 
provide in vivo assessment of tissue metabolism without the use of ionizing radiation. MRS is 
thus highly interesting for diagnosis and for prediction and assessment of tumour therapy 
response, both in cancer research and in the clinical setting (Gonzalez Hernando et al., 2010). 
MRS for quantitative assessment of cell metabolism has shown great potential as a tool for 
cancer-related diagnostics, e.g. as an indicator of tumour aggressiveness in breast cancer (Chan 
et al., 2016). 
Quantitative assessment of brain metabolism is another major field of application for MRS. By 
referring to the anatomical information from MR images (MRI) that are acquired prior to the 
MRS scan, the operator can control the position from which the spectroscopic information is 
acquired with high precision by using spectrum localization methods. MRS can thereby provide 
valuable information for diagnosis of, e.g., epilepsy and multiple sclerosis by measuring 
quantities of metabolites in carefully selected areas of the brain (Stagg & Rothman, 2013). 
Because MRS is non-invasive and easy to perform in sensitive areas of the body, it is currently 
the preferred tool for quantification of metabolites in the brain.  
However, in order to calculate metabolite concentrations from MRS data, individual spectra 
from each single metabolite that is expected to be found in the measured sample are required. 
Such spectra are generated separately, either by simulating them using specialized computer 
software, or by collecting MRS spectra from separate phantoms, each containing one of the 
individual metabolites. The collection of the individual spectra is then referred to as a basis set, 
and it is thus specific to the particular tissue that is being investigated, but also to the specific 
magnetic field strength, pulse sequence and timing parameters that are used in the study. The 
calculation of the metabolite concentrations is then performed using a modelling software 
which scales and fits the basis set components to the measured MRS data of the sample.  
At present, the preclinical 7T MR system at the University of Gothenburg (GU) is used in 
several studies, such as studies on tumour metabolism in relation to response to treatment and 
effects on the normal mouse brain after exposure to incidental irradiation from cancer 
radiotherapy. A computer software for simulation of basis sets was recently developed at GU 
(Jalnefjord et al., 2018), and validated in a master thesis for a clinical MR system using the 
modelling software LCModel (Pettersson, 2017). However, a standardized method for 
calculation of metabolite concentrations from preclinical MRS data is not available. Such 
methods are specifically created for a particular MR vendor and for predetermined MRS 
protocol parameters, and the previously developed software therefore requires adaption and 
validation for use on the preclinical 7T MR system.  
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2 Aim 
The general purpose of this project was to develop, validate and apply a method for non-
invasive quantification of metabolites from in vivo MRS at the preclinical facility at GU. 
Specifically, to 1) adapt a method based on simulations and LCModel analysis for the point 
resolved spectroscopy (PRESS) sequence used at the preclinical MR system, 2) validate the 
method performance by measurements on a phantom with known metabolic composition, and 
3) evaluate the method in the preclinical setting by determination of the metabolic composition 
in the healthy rodent brain and in solid tumours of a mouse model of human cancer. 
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3 Theoretical background 
Magnetic resonance spectroscopy (MRS) is a non-invasive method that can be used to measure 
concentrations of metabolites within a defined volume inside the body. The following sub-
sections will explain the principles of MRS and how it can provide metabolic information. 
3.1 Physics of MRS 
When a magnetic field is applied across an object, such as a body, it will interact with the 
magnetic moment of, e.g., hydrogen (1H) nuclei (often referred to as spin), within the object, 
and cause them to precess around the direction of the magnetic field. The frequency of this 
precession is called the Larmor frequency, 𝑓𝐿, and it will vary depending on the strength of the 
magnetic field, 𝐵0, and the gyromagnetic ratio, 𝛾, according to the Larmor equation (1).  
 
 
The magnetic moment of a hydrogen nucleus can exist in quantum states either parallel or anti-
parallel to the direction of the applied magnetic field. Because the parallel state is of lower 
energy it is favoured over the anti-parallel state and as a result there is a net magnetisation in 
the direction of the magnetic field. This net magnetisation is the origin of the MRS signal, which 
is picked up by receiver coils. 
Using transmit coils, it is possible to transmit radio frequent (RF) electromagnetic waves 
through the object. If the frequency of the RF waves, 𝑓𝑅𝐹, coincides with the Larmor frequency 
of the protons, the system will be excited, i.e. the net magnetisation, 𝑀, will be rotated away 
from the applied magnetic field. The rotation angle, 𝛼, is dependent on the RF pulse duration, 
𝑡, and the strength of the magnetic component of the RF pulse, 𝐵1, according to equation (2). 
An illustration of the excitation can be seen in Figure 1. 
 
 𝛼 = 𝛾𝐵1𝑡 (2) 
 
As the RF pulse is switched off, M will, once again, only experience the magnetic field in the 
𝐵0-direction, and start to precess around it. The component of M that is perpendicular to 𝐵0 
will induce a current in the receiver coil, which is acquired as a signal, the so-called free 
induction decay (FID), by the receiver system. Because the nuclei of a molecule, such as a 
metabolite, can have varying Larmor frequencies (further explained in section 3.2), the FID 
will contain multiple frequencies and can, after Fourier transformation into the frequency 
domain, be presented as a spectrum containing information on the amplitudes of the various 
Larmor frequencies found inside the sample. It is through this spectrum that the metabolic 






   
4 
Because each nucleus in the excited system will experience fluctuation in the applied magnetic 
field, the transversal component of M will diminish over time. This phenomenon is called 
transversal or T2 relaxation and the rate of the T2 relaxation varies between different molecules. 
As such, the individual signal strength of each molecule in a spectrum acquired from an MRS 
measurement will vary depending on the time between the excitation of the system and 
acquisition of the signal, the so-called echo time (TE).  
Since the gyromagnetic ratio is nuclei-specific it is necessary to decide which nucleus or isotope 
to build the pulse sequence parameters around. The most common isotope used for MRS is 1H 
because of its high natural abundance and relative sensitivity. However, other isotopes do also 




Figure 1: The net magnetic moment, M, will precess around the external magnetic field, 𝑩𝟎, at the 
Larmor frequency, 𝒇𝑳. When a radio frequent (RF) electromagnetic wave with a frequency, 𝒇𝑹𝑭, 
equal to 𝒇𝑳 enters the system during a time t, M will rotate perpendicular to the magnetic field of 




3.2 Chemical shift and J-coupling 
The nuclei that provide the signals used in MRS are almost exclusively part of molecule 
structures; in one of the simplest cases, the two hydrogen nuclei in water. Depending on the 
chemical structure of the molecule, electrons will be attracted to certain parts of the molecule 
which leads to variations in electron distribution. When a magnetic field is applied over an 
electron cloud, a current is induced which in turn creates small local magnetic fields. The local 
magnetic fields either shield against or enhance the strong external magnetic field. Nuclei on 
different locations in the molecule structure will thus experience slightly different net magnetic 
fields, and thereby precess at slightly different frequencies. The shift in Larmor frequency 
mediated by the electron cloud is called the chemical shift. Because the chemical shifts are 
specific for each molecule, they will lead to a unique spectrum for each molecule.  
The Larmor frequency shifts will differ depending on the strength of the external magnetic field 
of the MR system. It is therefore common to state the relative chemical shift against some 






· 106 𝑝𝑝𝑚 (3) 
 
where 𝛿 is the chemical shift in parts per million (ppm), 𝑓𝑠𝑎𝑚𝑝 is the sampled frequency and 
𝑓𝑟𝑒𝑓 is the frequency of the reference compound. Measuring the chemical shift in this way 
makes it independent of the strength of the external magnetic field, which facilitates comparison 
of spectra obtained at different field strengths. 
In addition to chemical shifts, the spectrum of a certain metabolite may also contain patterns 
caused by indirect dipole-dipole coupling, also called J-coupling. The J-coupling can be 
explained as indirect interactions between the spins mediated via the local electrons. The effect 
of the J-couplings is independent of the external magnetic field and can be observed as a 
splitting of peaks in the spectrum, typically of about 1-15 Hz for 1H. An illustration of the 




Figure 2: Due to local magnetic fields, the nuclei within a metabolite (here showing 𝜸 -
aminobutyric acid) will resonate at different Larmor frequencies and thus give rise to shifts in the 
spectrum. Because of the indirect interactions of spins (J-coupling), the peaks in the spectrum can 
also appear split 
 
 
3.3 Basis set and modelling 
A basis set is a set of spectra of different, single metabolites that will, due to chemical shifts 
and J-couplings, possess their own unique spectral patterns. The pattern does, however, also 
depend on signal acquisition parameters, such as TE and magnetic field strength. When an 
MRS-measurement of tissue is performed, the resulting spectrum consists of a weighted sum 
of the spectra corresponding to all the metabolites contained within the measured sample. It is 
therefore possible to fit a basis set to the measured spectrum using some model fitting method, 
and thereby obtain information on the quantities of each detectable metabolite inside the 
sample. An illustration of how a basis set can be modelled to fit a measured spectrum is shown 




Figure 3: A basis set containing the simulated spectra of, in order from top to bottom, 
phosphocreatine, glutamate, myo-Inositol, lactate, creatine, N-acetylaspartate and choline (lower 
part in grey). The basis set is in this example fitted (upper part in red) to a measured spectrum of 
a phantom containing the aforementioned metabolites (upper part in black) 
 
There are two methods to construct the basis set required for a particular study: 1) performing 
individual MRS measurements on each of the metabolites expected to be found and 2) 
simulating the included spectra by quantum mechanical calculation of the time evolution of a 
spin system under the influence of an MR pulse sequence. Until recent days, simulation of basis 
sets was difficult due to limitations in computing power. But with the technology available 
Chemical shift (ppm) 
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today, simulation is usually preferred over measurements due to price concerns and time 
consumption.  
When simulating a basis set, it is important to perform the simulations under the same physical 
conditions as the planned MRS measurement. Otherwise the spectra of the basis set will not 
represent the corresponding true spectra, and the model will not fit well to the data. What 
metabolites to include in the basis set must be guessed based on prior knowledge of the 
metabolic content inside the measured sample. A basis set with too many metabolites can lead 
to “over-fitting”, meaning that the modelling algorithm finds metabolites that do not actually 
exist in the sample. A basis set with too few metabolites, on the other hand, can cause the 
modelling algorithm to overestimate the quantities of some metabolites or fail to perform a fit 
all together. 
3.4 The MRS pulse sequence 
The timing and characteristics of the gradient fields and RF pulses used for generating the MR 
signal in MRS determine the character of the spectrum. This is usually referred to as the pulse 
sequence. A pulse sequence commonly used in MRS is the point resolved spectroscopy, or 
PRESS, sequence. The PRESS sequence is a single-voxel sequence, meaning it aims to collect 
the signal from a specified volume inside the subject, e.g., from a particular region within the 
brain. This is achieved by performing a 90°-excitation of a slice in one spatial direction followed 
by two 180°-excitations of slices in the remaining two spatial directions. Only the volume which 
has been affected by all three excitations will be phased properly and provide a signal to the 
receiver coils at the time of acquisition. The position and width of the slices are selected by 
applying a magnetic field that increases in strength linearly across the object, a so-called 
gradient field. This will cause the Larmor frequency of the protons to also vary linearly across 
the object in the same direction as the applied gradient field. By transmitting RF pulses through 
the object with a certain frequency bandwidth, only the protons with a Larmor frequency within 
the bandwidth of the RF pulse will be excited. This allows excitation of a specific volume of 
interest (VOI). To assure that no spins outside the VOI contribute to the measured MR signal, 
it is common to use so called crusher gradients to cause these spins to phase out heavily.  
As described earlier, TE is the time between the 90°-excitation, i.e. the RF pulse that excites 
the spin system, and the acquisition of the signal. TE is an important parameter in MRS because 
it has an effect on which metabolites will be visible in the spectrum since the T2 relaxation rate 
varies between different metabolites. A sequence with the ability to achieve short TE will result 
in spectra where the majority of metabolites are still visible. On the other hand, a long TE may 
be desirable to remove the signals from unwanted metabolites with fast T2-relaxation rates. The 
main alternative sequence to PRESS in MRS is the stimulated echo acquisition mode (STEAM) 
sequence. Due to how the MRS signal is achieved, STEAM could, for a long time, reach far 
lower TEs compared with PRESS, at the price of a lower signal strength. With today’s 
technology, however, it is possible to reach short TEs (<35 ms) with the PRESS sequence as 
well, making it the often-preferred choice for use in MRS (Stagg & Rothman, 2013). An 




Figure 4: A diagram showing the timing of the point resolved spectroscopy (PRESS) sequence. RF 
represents the timing of the radio frequent pulses, with numbers indicating the flip angles that are 
imposed on the net magnetisation. Gx-z represent the slice selective gradients used to locally excite 
magnetization in the three spatial dimensions, respectively, and Acq indicates when the MRS 
signal is acquired by the spectrometer. Time is represented by the x-axis 
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4 Materials and method 
4.1 MR equipment 
Measurements were performed on a preclinical, horizontal-bore, 7T MR system (Bruker 
BioSpin MRI GmbH, Germany; software: ParaVision 5.1) equipped with water cooled 
gradients (maximum gradient strength 400 mT/m). A 72-mm volume coil and an actively 
decoupled 4-channel array rat brain coil (RAPID Biomedical Gmbh, Rimpar, Germany) were 
used for signal transmit and receive, respectively.  
4.2 Simulations 
All basis sets used for modelling were simulated using an in-house built MATLAB 
(MathWorks, Natick, USA) software (Jalnefjord et al., 2018) based on a recently developed 
simulation technique (Zhang et al., 2017). The software was originally developed for a clinical 
3T MR system (Philips Achieva, The Netherlands, software release: 5.1.7.) with fundamentally 
different parameter definitions and validated in a previous master thesis project (Pettersson, 
2017). In this work, a modified version of this software was used, which had been adapted for 
use on the preclinical 7T MR system. The adaption included importation of pulse sequence 
parameters and minor adjustments to the gradient propagator definitions. Experienced based 
user instructions of the software and information on which parameters are required for 
simulation can be found in Appendix A.  
To avoid loss of signal due to chemical shift related spatial displacement, a simulated field of 
view (FOV) of 7×7×7 mm3 (~175-200 % of the measured VOI-size) was used. As an example, 
a shift of 1 ppm from the centre frequency at 2.95 ppm corresponds to a spatial shift of 0.5 mm 
or less with the parameters used in this project. To achieve high-quality simulated spectra a 
spatial distance between sampling points of 0.175 mm was used in all simulations. The amount 
of sampling points used in the FID was 16 384 and the acquisition time used was 2 s. Values 
for chemical shifts and coupling constants were based on previous works (Govind et al., 2015; 
Govindaraju et al., 2000). Since these values were obtained at 37 °C they had to be temperature 
adjusted for the phantom measurements that were performed at 25 °C. The temperature 
adjustment method is described elsewhere (Wermter et al., 2017). All simulations were based 
on pulse sequence parameters, including RF-pulses, gradients and timings used, directly 
imported from files generated by ParaVision after each measurement. 
4.3 Phantom validation 
4.3.1 Phantom 
To evaluate the accuracy of the simulations, measurements were performed on a cylindrical 
plastic phantom containing a mixture of metabolites of known concentrations (Table 1). In 
addition to the metabolites, the mixture also contained sodium hydroxide and potassium 





Table 1: Concentrations of metabolites in the phantom solution used for validation of the 
simulation code 
Metabolite Concentration (mM) 
Creatine + Phosphocreatine 10  
Choline 2 







Multiple phantom scans were performed using the PRESS sequence with repetition time (TR): 
2500 ms and TE: 35, 72, 108 and 144 ms with corresponding number of signal averages (NSA): 
512, 1024, 1024 and 2048 respectively. The number of complex data points in the FID was 
2048. An offset frequency of -510.49 Hz was used. The VOI size was 3.5×3.5×3.5 mm3 and 
was positioned in a region of high signal intensity, based on the image intensity in multiple 
reference images (Bruker triPilot) acquired in all three orthogonal directions. Automatic 
shimming was performed to improve the homogeneity of the static magnetic field within the 
VOI. A full width at half maximum (FWHM) of less than 30 Hz, based on a PRESS waterline 
acquisition covering the VOI, was regarded adequate for the MRS experiment. 
4.3.3 Post-processing 
The measured spectra were linearly modelled using simulated basis sets of corresponding TE 
to acquire relative concentrations to the reference metabolites choline + phosphocholine. The 
modelling was performed using the software LCModel and included the metabolites shown in 
table 1. A Cramér-Rao lower bound (CRLB) was provided by LCModel as an estimation of the 
accuracy of the calculated metabolite concentrations. Only metabolites found by LCModel with 
a CRLB of 20 % or less were considered reliable enough to include in the results. 
The relative metabolite concentrations are affected by TE due to the difference in T2 relaxation 
between the measured metabolites and the reference metabolites. In order to compensate for 
this, all relative concentrations for each metabolite were plotted as a function of TE and fitted 
to an exponential function. The initial value of this function was then extracted to acquire the 
relative concentrations at TE = 0 ms, i.e. without any T2 relaxation effects. 
4.4 In vivo experiments 
4.4.1 Animal models and experimental setup 
The in vivo cancer experiments were conducted on female BALB/c nude mice with 
subcutaneously grown xenografts of the human small intestine neuroendocrine tumour (GOT1 
(Kölby et al., 2001)), and experiments on the brain were conducted on healthy C67BL/6 mice. 
The mice were anaesthetized using air and isoflurane (2-3 %, Isoba vet., Schering-Plough 
Animal-health, Denmark) during the MR experiments, body temperature was maintained using 
a heating pad and a pressure sensitive pad was used to monitor breathing. Total scan time was 
approximately 10 min for the cancer experiment and 20 min for the brain experiment. The 
animals were fed with standard diet and water ad libitum. 
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The experiments of this study were approved by the regional animal ethics committee in 
Gothenburg. 
4.4.2 Experiments 
The pulse sequences, reference scans and acquisition parameters described for the phantom 
measurements were also used for the in vivo measurements with some exceptions mentioned 
here. The NSA was 256 for the tumour measurement and 512 for the brain measurement and a 
TE of 30 ms was used in all in vivo experiments. For the tumour measurement, the VOI size 
was 4×4×4 mm3, positioned in the central tumour region (Figure 5). For the brain measurement, 
the VOI size was 2.95×6.3×5 mm3, positioned in the central area of the brain without including 
fat around the brain (Figure 6). For the brain measurement, transversal, anatomical high-
resolution images (RARE) were acquired to further aid with the positioning of the VOI. The 
setup can be seen in Figure 5. 
 
 
Figure 5: Geometrical positioning of the volume of interest (pink box, solid line) used in the in vivo 
MRS experiment of the human neuroendocrine tumour (hyper-intense mass in the lower part of 
the image) growing subcutaneously in a nude mouse (upper left half of the image). The dotted 
pink lines represent the VOI in other slices. The dark vertical bands appearing in the image are 




Figure 6: T1 weighted, transversal RARE image (left) of the healthy mouse brain showing the 
geometrical positioning of the volume of interest (pink box, solid line) used in the in vivo MRS 
experiment. The dotted pink lines represent the VOI in other slices. The sagittal view (right) shows 
the longitudinal extent of the MRS volume 
 
4.4.3 Post-processing 
Linear modelling was performed in the same way as in the phantom validation. The basis set 
for the tumour measurement contained the following metabolites: choline, phosphocholine, 
glycerophosphocholine, myo-Inositol, scyllo-Inositol, lactate, N-acetylaspartate, taurine, and 
glycine. Except for glycine, the basis set for the healthy brain measurement contained the same 
metabolites as well as creatine, phosphocreatine, aspartate, N-acetylaspartylglutamic acid, 
glutamine, glutamate, 𝛾-aminobutyric acid, α-glucose, and guanine. All fits also included lipids 
and macromolecules from the built-in database of LCModel. The frequency ranges for the fit 





The spectra of individual metabolites generated by the simulations were in agreement with the 
expected appearance based on chemical shifts and J-couplings. The simulated spectrum of 
lactate at TE = 30 ms and 7T is shown in Figure 7 as an example of the simulation output. The 
chemical shifts of 4.09 and 1.31 ppm and the J-coupling split of 6.9 Hz of both peaks can be 
observed in the spectrum, as well as the split into four and two peaks for the peak at 4.09 and 
1.31 ppm, respectively, due to multiplicity.  
 
 
Figure 7: Simulated spectrum of the lactate metabolite at TE = 30 ms and 7T 
 
5.2 Phantom validation 
In general, the simulated basis sets were well fitted to the measured phantom data, with only 
minor observable residual structures that the model could not account for. The most notable 
remaining residual structures were observed at 2.6-2.8, 3.74 and 4.03 ppm. The residual 
structures at 4.03 ppm increased with increasing TE. The fit of the basis set to the spectra from 
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Figure 8a: The spectrum acquired from the phantom at TE = 35 ms (black) with fitted basis set 
superimposed (red). The base line is visible in grey beneath the spectrum. The part of the signal 
not accounted for by the basis set, i.e. the residual, is shown above the spectrum. The 
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Figure 8b: The spectrum acquired from the phantom at TE = 72 ms. Note the increasing residual 
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Figure 8c: The spectrum acquired from the phantom at TE = 108 ms. Note the increasing residual 
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The measured relative concentrations to creatine + phosphocreatine for glucose, myo-Inositol, 
lactate, N-acetylaspartate, and choline at TE = 35, 72, 108 and 144 ms, as well as the 
exponential fit to the data points, are shown in Figure 9.  
 
  
Figure 9: Measured concentrations relative to creatine + phosphocreatine for glucose (Glu), myo-
Inositol (Ins), lactate (Lac), N-acetylaspartate (NAA), and choline (Cho) based on fits of basis sets 
to phantom measurements at TE = 35, 72, 108 and 144 ms in LCModel. The dotted lines show the 
exponential fit to the data points. The concentration ratio of glutamate and myo-Inositol coincide 









The difference between the calculated relative concentrations to creatine + phosphocreatine, 
with T2 relaxation effects compensated for, and the corresponding relative concentrations listed 
for the phantom solution (Table 2) were small in general. The exception was lactate where the 
calculated relative concentration divided by the listed relative concentration was 0.56. When 
calculating the relative concentration using only the measurements for TE = 72, 108 and 144 
ms, however, lactate received a calculated relative concentration of 0.49 which corresponds to 
a ratio between the calculated and listed relative concentrations of 0.98.  
 
Table 2: Calculated relative concentrations to creatine + phosphocreatine for glucose (Glu), myo-
Inositol (Ins), lactate (Lac), N-acetylaspartate (NAA), and choline (Cho) with T2 relaxation 
compensated for based on the exponential fits to the data points shown in Figure 9. The listed 
relative concentrations for the phantom are also shown. The ratio is the calculated relative 
concentration divided by the listed relative concentration  
Metabolite Calculated Listed Ratio 
Glu 1.35 1.25 1.08 
Ins 0.79 0.75 1.05 
Lac 0.28 0.5 0.56 
NAA 1.17 1.25 0.94 
















5.3 In vivo experiments 
The fit of the basis set to the in vivo tumour data was good, with little or no visible residual 
structures (Figure 10). The metabolites found by the modelling with a CRLB of 20 % or less 
were choline, phosphocholine, myo-Inositol, lactate, N-acetylaspartate, taurine and glycine. In  
addition to this, the combined concentration totCho (choline + phosphocholine + 
glycerophosphocholine) was also found with a CRLB of 20 % or less. 
 
 
Figure 10: The spectrum acquired from the in vivo measurement on a subcutaneous tumour in a 
mouse model of a human neuroendocrine tumour at TE = 30 ms (black) with fitted basis set 
superimposed (red). The base line is visible in grey beneath the spectrum. The part of the signal 
not accounted for by the basis set, i.e. the residual, is shown above the spectrum. The metabolite 
contributions to the most significant peaks in the spectrum are shown for myo-Inositol (Ins), 
glycine (Gly), choline + phosphocholine + glycerophosphocholine (totCho), taurine (Tau), N-





The fit of the basis set to the measured in vivo brain data was good in general, with few residual 
structures (Figure 11). The fit with the base line included can be seen in Appendix B. The 
individual metabolites found by the modelling with a CRLB of 20 % or less were glutamate, 
phosphocreatine, myo-Inositol, N-acetylaspartate, N-acetylaspartylglutamate, taurine, 
phosphocholine and glycine. In addition to this, the combined concentrations totCho (choline 
+ phosphocholine + glycerophosphocholine), totCr (creatine + phosphocreatine) and Glx 
(glutamate + glutamine) were also found with a CRLB of 20 % or less. 
 
 
Figure 11: The spectrum acquired from the in vivo measurement on a healthy mouse brain at TE 
= 30 ms (black) with fitted basis set superimposed (red) and the baseline subtracted. The part of 
the signal not accounted for by the basis set, i.e. the residual, is shown above the spectrum. The 
modelling was performed from 1.8 ppm to avoid miss-fits due to the large contribution of fat 
present at lower ppm. The metabolite contributions to the most significant peaks in the spectrum 
are shown for creatine + phosphocreatine (totCr), glutamate + glutamine (Glx), glycine (Gly), 
myo-Inositol (Ins), choline + phosphocholine + glycerophosphocholine (totCho), N-acetylaspartate 
(NAA) and N-acetylaspartylglutamate (NAAG). The spectrum with the baseline included can be 





In this project, a method for non-invasive quantification of metabolites from in vivo MRS at the 
preclinical facility at the University of Gothenburg was developed and validated. The method 
was based on a previously developed software for simulation of basis sets for determination of 
metabolite concentrations from MRS measurements, but was designed for use on a 3T clinical 
system with vendor specific parameter file structure. The software had to be adapted for use on 
the preclinical 7T MR system which required reprogramming of a MATLAB-based code to 
read the required parameters from the preclinical system, as well as validation experiments, 
including phantom measurements and in vivo measurements on a mouse model of human cancer 
and the healthy mouse brain. 
In general, the validation of the simulation software showed few residual structures in the fit of 
the phantom data which implies that the simulated spectra were of good quality.  
There were, however, a few recurring residual structures that could be observed for all TE, most 
notably at chemical shifts at 4.03 ppm. A possible explanation is the fact that the phantom 
solution available to us was outdated by 2 years (labelled with a durability of 1 year). The 
chemical structure of some of the metabolites may have changed over time with possible effects 
on the chemical shifts and J-couplings. Since metabolic alterations were not accounted for in 
the simulation, they may have caused the residual structures observed in the spectrum 
evaluations. 
System imperfections may also cause spectrum artefacts and lead to residual structures. A 
comparison with a measurement on the same phantom solution performed on the clinical 3T 
MR system, and evaluated using the same simulation software revealed highly similar residual 
structures, which indicates that the 7T system did not cause the residual structures. The 
simulation software has also been validated in a previous master thesis using the clinical 3T 
MR system and a recently put together phantom solution, which did not show the residual 
structures apparent in the validation performed in this work. This makes it unlikely that the 
residual structures appeared due to programmatic errors in the simulation code.  
Spatial displacement of the VOI due to chemical shift is a common concern when performing 
MRS. If the VOI is placed too close to the border of the tissue structure of interest, there is a 
possibility that the VOI will end up outside the volume for metabolites with a significant shift 
from the reference frequency. This can lead to differences in the relative signal strength between 
peaks of the same metabolite at different frequencies and thus give rise to residual structures. 
In this work, spatial displacement due to chemical shift was accounted for by calculating the 
maximum possible displacement and restricting the VOI position accordingly, and VOI 
displacement should therefore not have caused the residual structures observed. 
It should be noted that the residual structures discussed above were small, and probably with 
little or no effects on in vivo evaluation of metabolite concentrations where physiological noise 
and magnetic field distortions are probably of greater concern.  
The relative concentrations calculated in the phantom validation showed very good results in 
general, with small deviations from the listed relative concentrations of the phantom solution. 
The exception was lactate which showed a ratio between the calculated and listed relative 
concentrations of 0.56. Interestingly, when excluding the first measurement of TE = 35 ms, this 
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ratio was improved to 0.98, which indicates that the large deviation may be related to issues 
with the first scan. 
In the phantom measurements for validation, a TR of 2500 ms was used which could have 
caused saturation effects due to inadequate longitudinal relaxation between successive scans. If 
relaxation rates differed between the metabolites it could have affected the calculated phantom 
concentrations. The longitudinal relaxation rate of a metabolite is dependent on its immediate 
environment. However, based on T1 relaxation rates acquired for metabolites in the brain in 
previous works, the expected error in the relative concentrations for the validation performed 
in this work due to differences in T1 relaxation between metabolites would be approximatively 
15 % or less (Xin et al., 2013). In future phantom measurements it is suggested to use a higher 
TR to reduce the effects of T1 relaxation. 
The ability to study metabolites non-invasively and longitudinally in tumours is of high interest 
for clinical and preclinical research. For example, lactate, taurine, choline and glycine have 
shown elevated concentrations in colorectal cancer compared with normal tissue, and 
concentrations have been correlated with tumour aggressiveness in breast cancer (Chan et al., 
2009; Chan et al., 2016). Furthermore, lower pre-treatment concentrations of glycine in locally 
advanced rectal cancer has been correlated with increased progression free survival after 
neoadjuvant chemotherapy (Redalen et al., 2016). The method used in this work for determining 
metabolites in vivo in tumours showed good results, and lactate, taurine, choline and glycine 
were all detected by LCModel with a CRLB of less than 20 %, indicating that the levels of these 
metabolites were accurately determined by the method validated in this work. 
When performing the measurements on the healthy mouse brain, small VOIs were first 
attempted to cover specific anatomical parts of the brain, such as the cortex or the hippocampus. 
When attempting this, however, the signal to noise ratio (SNR) was too poor to accurately 
perform a fit to the spectrum. To improve the SNR, a larger VOI was chosen to cover a 
significant part of the brain. However, measurements with the larger VOI caused a significant 
peak to appear in the range [0, 1.8] ppm. This was likely caused by acquisition of fat signals 
from outside the VOI due to the previously mentioned spatial displacement. The appearance of 
this peak made fitting of the basis set difficult in the lower ppm range and the fit was therefore 
performed in the range [1.8, 4.2] ppm instead. Unfortunately, this meant that lactate and alanine, 
two metabolites commonly found in the brain, could not be fitted by LCModel as their most 
significant peaks are present below 1.8 ppm. LCModel was, however, able to accurately (CRLB 
< 20 %) detect Glx (glutamate + glutamine), totCr (creatine + phosphocreatine), myo-Inositol, 
NAA, NAAG, taurine, totCho (choline + phosphocholine + glycerophosphocholine) and 
glycine, all of which have been found in the healthy mouse brain in previous studies (Duarte et 
al., 2014; Kulak et al., 2010; Rana et al., 2013).  
A significant baseline was observed in the in vivo measurements. The baseline is estimated by 
LCModel to compensate for the contributions of macromolecules (MM) and lipids and it is 
important to be aware of the shape of the baseline since it may have an effect on the quality of 
the fit. In the in vivo modelling, the baseline was expected to be significant due to the presence 
of MMs and lipids. To simplify the estimation of the baseline done by LCModel, a metabolite-
nulled spectrum, containing only spectral patterns from MM and lipids, can be measured and 
subtracted for each in vivo spectrum. Although this will reduce the SNR, there will be fewer 
corrections left to compensate for by LCModel. Subtraction of metabolite-nulled spectrums 
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was not performed in this work, but may potentially be used to improve the results in future 
studies. 
Future improvements of the method could include expanding the method for absolute 
quantification of metabolite concentrations, this however requires knowledge of the water 
concentration in the VOI which is difficult to measure non-invasively. The simulation software 
could be further developed to include additional pulse sequences which may be of interest when 
performing in vivo MRS, such as the STEAM sequence. T2-relaxation effects could also be 
included in the simulation software to provide more accurate metabolite concentrations at 




In this work, a method for preclinical in vivo, non-invasive metabolite quantification based on 
MRS experiments was developed and validated. The method was based on a previous master 
thesis project and was developed for a clinical MR system. It therefore required programmatic 
adjustments in order to export correct data from the preclinical system, as well as thorough 
validation by phantom measurements. The method will provide a necessary means for 
evaluation of both current and future MRS studies at the preclinical MR facility at the 
University of Gothenburg, with immediate application on, e.g., ongoing studies on cancer 
therapies.  
Parameters describing the pulse sequence could be extracted successfully from the preclinical 
MR system and thus enabled creation of basis sets through simulations. The validation of the 
method performance revealed basis sets well fitted to the spectra, as well as accurately 
determined metabolite concentrations. The in vivo experiments on the mouse model of human 
cancer and on the healthy mouse brain both showed well fitted basis sets. The cancer 
measurement resulted in metabolite profiles typical of cancer and the brain measurement 
resulted in metabolic profiles which were in agreement with previous MRS studies on healthy 
mouse brains.  
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Appendix A – The simulation code 
A.1 Experienced based user instructions 
To perform the simulations, the code requires a multitude of parameters, these are explained in 
section A.2. It is also necessary to define names, chemical shifts, and coupling constants of all 
metabolites to be simulated. The simulation itself is based on the principles of quantum 
mechanics and creating density operators that describe the average quantum states of the system 
at a given time.  A more detailed explanation on how the quantum physics approach has been 
implemented into the simulation code is explained in (Jalnefjord et al., 2018). Once the 
simulation of the chosen metabolites is completed, a RAW-file containing their FID will be 
generated for each metabolite, as this is the file format accepted by the LCModel software. The 
RAW-files can then be imported and used to create a basis set in LCModel. The reference 
metabolite used for calculation of chemical shift in LCModel is 4,4-dimethyl-4-silapentane-1-
sulfonic acid, or DSS, and a spectrum for this metabolite is therefore generated at the start of 
every simulation. A pseudocode explaining the general sequence of the simulation code can be 




Two different types of parameters are required by the code for the simulation to function: 
simulation parameters and pulse sequence parameters. The simulation parameters are changed 
directly by the user in the code and should be modified before every simulation. The pulse 
sequence parameters are extracted automatically from specific files generated by ParaVision.  
 
Define simulation parameters 
Define pulse sequence parameters 
Simulate a reference peak for DSS 





Figure 12: Pseudocode for the general 
sequence of the simulation code used 
for creation of basis sets 
 
 
A.2.1 Simulation parameters 
The following is a list of simulation parameters that require user input before every simulation: 
 𝐵0 field strength  
 Spectrometer frequency 
 Simulated FOV  
 Resolution 
 Sampling points 
 Acquisition time 
 Metabolites to be simulated 
Special caution should be taken when choosing the simulated FOV as this must be appropriately 
large so that there is no signal lost. The simulated FOV must therefore always be at least as 
large as the VOI used in the measurement and, due to the spatial displacement from the 
chemical shifts, most likely significantly larger. Do also note that increasing the resolution will 
increase the amount of spatial points simulated and therefore also the simulation time. Because 
the simulation uses a one-dimensional approach (Zhang et al., 2017), the simulation time scales 
linearly with the resolution. In other words, if the resolution is doubled in each direction so too 
will the simulation time be doubled. 
A.2.2 Pulse sequence parameters 
The files required by the code to import necessary pulse sequence parameters from the Bruker 
system are automatically generated by ParaVision after each measurement. The exception to 
this is the preemphasis file which can be found locally in the ParaVision directory. The 
following is a list of the files required as well as the parameters imported from them: 
 pulseprogram 
o Indexes for gradient strengths 
o Indexes for pulse times and pulse shapes 
o Phase cycling scheme 
 acqp 
o Gradient trim values 
o Delays 
 method 
o Gradient calibration constant 
o Pulse durations 
 spnamN, N = 1,2,3, … 
o Pulse shape of pulse N 
 Preemphasis file 
o Ramp time 
The pulseprogram file contains information, or indexes, about the timings, pulses and gradients 
to be used in the pulse sequence. The actual values for these indexes are then acquired from the 
acqp and method files. The values for the gradient strengths however, are not acquired directly 
but are instead calculated using the gradient calibration constant and gradient trim values. It 
could also be of interest to know that the ramp time parameter is not the true ramp time used in 
the pulse sequence. Rather, it is the time it would take for an ideal ramp to reach the plateau of 
the gradient with the same dephasing as the true ramp. Therefore, this parameter is not 





Figure 11: The spectrum acquired from the measurement of a healthy mouse brain using TE = 30 
ms (black) with fitted basis set superimposed (red). The base line is visible in grey beneath the 
spectrum. The part of the signal not accounted for by the basis set, i.e. the residual, is shown above 
the spectrum. The modelling was performed from 1.8 ppm to avoid miss-fits due to the large 
contribution of fat present at lower ppm 
 
